Efficacy and Safety of Apatinib as Third-line Therapy for Primary Pulmonary Lymphoepithelioid Carcinoma

Sponsor
Guangzhou Institute of Respiratory Disease
Study ID
NCT03709953
Phase
PHASE2
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Apatinib — DRUG
    500 mg，po，QD； 28 days every cycle

Study Details

Currently, there is no standard treatment for primary pulmonary lymphoepithelioid carcinoma. Apatinib is a new kind of Vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase inhibitors (TKIs). A disease-control rate of 75% was found in lung cancer patients in a phase II clinical study. Therefore, researchers hope to explore the efficacy and safety of apatinib in the treatment of primary pulmonary lymphoepithelioid carcinoma.

Key Dates

Start date
Oct 19, 2018
Status verified
Oct 2018
Primary completion
Mar 31, 2021
Completion
Apr 30, 2021

Study Design

Enrollment
33 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: apatinib
    apatinib, 500 mg, po, QD; 28 days every cycle

Primary Outcome Measure

PFS [ Time Frame: 24 months ]

Central Contacts

Related Studies